EMA — authorised 21 April 2021
- Marketing authorisation holder: GlaxoSmithKline (Ireland) Limited
- Status: approved
🇪🇺 Jemperli in European Union
EMA authorised Jemperli on 21 April 2021
Marketing authorisations
EMA — authorised 21 April 2021
- Application: EMEA/H/C/005204
- Marketing authorisation holder: GlaxoSmithKline Trading Services Limited
- Local brand name: Jemperli
- Indication: Jemperli is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.
- Status: approved
Jemperli in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Jemperli approved in European Union?
Yes. EMA authorised it on 21 April 2021; EMA authorised it on 21 April 2021.
Who is the marketing authorisation holder for Jemperli in European Union?
GlaxoSmithKline (Ireland) Limited holds the EU marketing authorisation.